With cell therapy showing more promise lately, Unum Therapeutics Inc.'s series A funding will help advance its platform for cancer treatment based on an antibody-coupled T-cell receptor (ACTR), in which T cells are genetically programmed so that they can go after a variety of cancers via targeting antibodies, and are not restricted by a particular antigen.